Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more
sensitive to the drug.
PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and
temozolomide in treating patients with relapsed glioblastoma.